Stephen Taub Premium From Deep Losses to Remarkable Gains: Biopharma’s Wildest Year in Recent Memory A spring pivot in sentiment turned one of the sector’s toughest stretches into a breakout year for the specialist funds. Stephen Taub January 14, 2026